September 21, 2017 2:15 AM ET


Company Overview of Valeant Canada Ltd.

Company Overview

Valeant Canada Ltd., a specialty pharmaceutical company, manufactures, distributes, and markets pharmaceutical products in the fields of neurology, psychiatry, pain management, and dermatology. It also focuses on neurology, such as pain management, Parkinson's disease, Epilepsy, multiple sclerosis, Huntington's disease, and ALS; infectious diseases, which include Hepatitis, HIV, SARS, and RSV; Dermatology, including Psoriasis, Eczema, Acne, Rosacea, Actinic Keratoses, Squamous Cell Carcinoma, and anti-fungals; and sleep disorders. Valeant Canada Ltd. was formerly known as ICN Canada Ltd and changed its name to Valeant Canada Ltd. in September 2004. The company was founded in 1956 and is base...

4787 Levy Street

Montreal, QC H4R 2P9


Founded in 1956





Key Executives for Valeant Canada Ltd.

Chairman of Valeant Pharmaceuticals International and CEO of Valeant Pharmaceuticals International
Age: 58
Human Resources Director
Compensation as of Fiscal Year 2017.

Valeant Canada Ltd. Key Developments

Valeant Plans to Split its Business into Three Segments

Valeant announced that it was planning to split its business into three segments: the so-called "durable growth" segment will incorporate the Bausch & Lomb eyecare business and most of the company's international sales; the "growth" segment will incorporate its Salix and Dendreon subsidiaries as well as its dermatology businesses; while the "cash-generating" segment will include neurology and other drugs.

Valeant Canada Expands its Canadian Manufacturing and Export Capacity

Valeant Canada is expanding its Canadian manufacturing and export capacity. The company is investing a total of USD 27.5 million in its Steinbach, Manitoba and Laval, Quebec manufacturing facilities. It will invest USD 15 million at Steinbach by the end of 2016, including USD 7 million in upgrades to product manufacturing technology and USD 8 million for the transfer of North American production of Xifaxan (rifaximin) and Apriso (mesalamine). The funds are intended to support the facility's growth and expand its role as an exporter of healthcare products, while ensuring robust security for products traveling through international distribution channels. Xifaxan is prescribed to relieve symptoms of hepatic encephalopathy and irritable bowel syndrome and Apriso is used to treat ulcerative colitis. Valeant also announced USD 12.5 million of investments in its Laval, Quebec facility, which includes USD 10 million to upgrade product manufacturing technology, as well as USD 2.5 million associated with the transfer of production of Arestin (minocycline hydrochloride), an antibiotic treatment for periodontal disease, to Laval.

Valeant Canada Announces Investment of $10 Million in Laval Facility to Increase and Secure its Export Capacity

Valeant Canada continued the expansion of its Canadian manufacturing and export capacity with a $10 million investment in its Laval, Quebec headquarters to enhance the site's manufacturing and export capabilities. The fourth notable investment announcement by Valeant in Canada in recent weeks, includes modernization of the plant with enhanced manufacturing technology to ensure robust security of Valeant-manufactured products as they move through international distribution channels. The investment announced in Laval plant will ensure compliance with U.S. regulatory requirements and maintain the facility's ability to service significant North American manufacturing mandates. It currently exports 75% of its products into markets across the continent. The upgrades for product manufacturing will take place by the end of 2016.

Similar Private Companies By Industry

Company Name Region
1127466 B.C. Ltd. Americas
4everPets Ltd. Americas
9037136 Canada Inc. Americas
AAA Heidelberg Inc. Americas
Ab Biotech Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Valeant Canada Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at